HighTower Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-35,641
Closed -$1.46M 3699
2022
Q4
$1.46M Buy
+35,641
New +$1.48M ﹤0.01% 1456
2021
Q3
Sell
-16,161
Closed -$836K 3465
2021
Q2
$836K Sell
16,161
-33,866
-68% -$1.7M ﹤0.01% 1753
2021
Q1
$2.52M Sell
50,027
-92
-0.2% -$4.9K 0.01% 1015
2020
Q4
$2.61M Sell
50,119
-1,053
-2% -$50.4K 0.01% 799
2020
Q3
$2.23M Buy
+51,172
New +$2.24M 0.01% 840
2018
Q4
Sell
-327,271
Closed -$15.9M 2385
2018
Q3
$15.9M Buy
+327,271
New +$15.5M 0.11% 195
2017
Q3
Sell
-5,749
Closed -$247K 2370
2017
Q2
$247K Buy
5,749
+1
+0% +$42 ﹤0.01% 1742
2017
Q1
$240K Buy
5,748
+200
+4% +$8.15K ﹤0.01% 1672
2016
Q4
$217K Sell
5,548
-200
-3% -$8.14K ﹤0.01% 1640
2016
Q3
$255K Buy
5,748
+100
+2% +$4.54K ﹤0.01% 1530
2016
Q2
$236K Hold
5,648
﹤0.01% 1420
2016
Q1
$226K Sell
5,648
-23,427
-81% -$993K ﹤0.01% 1757
2015
Q4
$1.49M Sell
29,075
-1,449
-5% -$73.8K 0.02% 757
2015
Q3
$1.43M Sell
30,524
-30,482
-50% -$1.84M 0.02% 730
2015
Q2
$3.8M Sell
61,006
-10,712
-15% -$667K 0.06% 339
2015
Q1
$4.43M Buy
71,718
+7,698
+12% +$456K 0.07% 328
2014
Q4
$3.46M Buy
64,020
+868
+1% +$47.4K 0.05% 393
2014
Q3
$3.35M Sell
63,152
-1,950
-3% -$99.1K 0.06% 363
2014
Q2
$3.38M Sell
65,102
-9,240
-12% -$446K 0.06% 363
2014
Q1
$3.48M Buy
74,342
+7,112
+11% +$336K 0.07% 334
2013
Q4
$2.96M Sell
67,230
-12,686
-16% -$528K 0.06% 344
2013
Q3
$3.08M Buy
79,916
+8,810
+12% +$333K 0.08% 294
2013
Q2
$2.51M Buy
+71,106
New +$2.4M 0.07% 310

Other funds holding XPH

HighTower Advisors's XPH Position: Q1 2023 in Review

HighTower Advisors sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2023, closing a stake of 35,641 shares — an estimated $1.46M sold.

HighTower Advisors first reported a position in XPH in Q2 2013 and held it in 23 quarters. The position peaked at $15.9M in Q3 2018. 61 funds tracked by Wall St. Rank hold XPH as of Q1 2023.

  • HighTower Advisors reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2023 after selling out during the quarter.
  • HighTower Advisors sold 35,641 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2023, an estimated $1.46M.
  • HighTower Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2013 and held it in 23 quarters.
  • HighTower Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $15.9M in Q3 2018.
  • 61 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.